Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19.
Rosie S JonesPatricia S SmithPaul H BergAmparo de la PeñaPaul P CookImad ShawaKathleen M KioussopoulosYu HuRobert J SchottPublished in: Clinical medicine insights. Circulatory, respiratory and pulmonary medicine (2022)
NCT04342897.
Keyphrases
- double blind
- placebo controlled
- clinical trial
- end stage renal disease
- phase ii
- sars cov
- coronavirus disease
- study protocol
- ejection fraction
- newly diagnosed
- phase iii
- chronic kidney disease
- prognostic factors
- randomized controlled trial
- squamous cell carcinoma
- patient reported outcomes
- radiation therapy
- acute respiratory distress syndrome
- respiratory failure